
Chlordiazepoxide, sold under the brand name Librium, is one of the oldest benzodiazepines still in use. Like every drug in its class, it strengthens the effect of gamma-aminobutyric acid (GABA), the brain’s main calming chemical messenger. More GABA activity means less anxiety, less muscle tension, and easier sleep, at least at first.
Its United States Food and Drug Administration (FDA) label lists three uses: anxiety disorders or the short-term relief of anxiety symptoms, withdrawal from alcohol, and apprehension before surgery. The label also says its usefulness beyond four months has never been formally assessed, and asks the physician to reassess it periodically. In practice, that reassessment rarely happens.
So, a drug written for a few days in a hospital or a few weeks of anxiety is still in the medicine cabinet years later. How does that happen, and what does it take to stop?
Two paths lead to the same place. One person is given chlordiazepoxide during a hospital stay for alcohol withdrawal and sent home with a prescription that keeps getting refilled. Another is started on it for anxiety, feels better, and is never told when or how it will end.
Within weeks, the brain adapts to the constant presence of the drug and turns down its own calming signal. The dose that once brought relief now only keeps withdrawal away. That state is physical dependence, and the FDA’s 2020 boxed-warning update says plainly that continued use of any benzodiazepine can cause it, with the risk rising with dose and duration.
Physical dependence is not addiction. A person who takes chlordiazepoxide exactly as prescribed and cannot stop without becoming ill does not have a behavior problem. They have a medical condition caused by a prescription, and the treatment for it is a slow medical taper, not a program.
The Ashton Manual, written by Professor C. Heather Ashton and published at benzo.org.uk, lists chlordiazepoxide in Table 1 of its first chapter with a half-life of 5 to 30 hours for the parent drug and 36 to 200 hours for its active metabolites. Half-life is the time it takes for the blood level of a drug to fall by half, so metabolites that linger for days keep blood levels fairly even between doses.
That is good news for tapering. Short-acting benzodiazepines wear off between doses, which causes interdose withdrawal, so every reduction lands on a nervous system that is already swinging. A long-acting drug lets each reduction settle in gradually, which is why Professor Ashton built her schedules around diazepam, a drug in the same long-acting family.
The same table gives the equivalence: 25 mg of chlordiazepoxide is roughly equal to 10 mg of diazepam. Professor Ashton notes that these figures come from clinical experience and vary between people, so they are the start of a conversation with your doctor, not a rule.
This is where a great deal of online advice goes wrong, including an earlier version of this article. The Ashton Manual recommends a diazepam switch for relatively short-acting benzodiazepines such as alprazolam and lorazepam, because a smooth decline in blood levels is not possible with those drugs. It adds that a switch may be needed for a long-acting drug of low potency, such as flurazepam, whose available doses are too coarse to taper.
Chlordiazepoxide is in neither group. In fact, the Manual’s second chapter names it as one of only three other benzodiazepines with a half-life similar to diazepam. So, most people taking chlordiazepoxide can taper it directly, without a crossover taper to a different drug.
The one real obstacle is the capsule. Chlordiazepoxide comes in 5 mg, 10 mg, and 25 mg capsules, and there is no reliable way to take three quarters of a capsule. A compounded liquid usually solves that without a change of drug, though a crossover taper to diazepam remains an option when it helps. His page on the Ashton Manual covers the Manual itself in more detail.
The shape is simple, even if the pace is not. The dose comes down in small steps, each step is held for a week or two or longer until the person feels steady, and the steps get smaller as the dose gets lower. The Maudsley Deprescribing Guidelines call this a hyperbolic taper, and the reason for it lives in the receptor.
An analogy that might help is the volume knob on an old radio. At the top of the dial, one notch down barely changes the sound. Near the bottom, that same notch is the difference between a whisper and silence.
Benzodiazepine receptors appear to behave the same way, so a cut that was easy at the start can be brutal near the end. While this is not a perfect analogy, it explains why the last steps of a taper must be the smallest.
A compounded liquid makes those small steps possible. A compounding pharmacy suspends the drug in a measured liquid, so a reduction can be a fraction of a milligram rather than a whole capsule. Dr. Leeds writes these prescriptions routinely and favors no one pharmacy.
Who sets the pace? The patient does. If a step brings symptoms that do not settle, the answer is to hold at that dose for as long as it takes, and the doctor must support the hold. If the steps are going well, patient and doctor may agree to move a bit faster, as tolerated. How the visits work is described on his medically supervised benzodiazepine tapering page.
Unfortunately, the number most people hear first is weeks. Professor Ashton wrote that the classic six-week withdrawal period used by many clinics and doctors is much too fast for people who have taken a benzodiazepine long term. Her rough guide for a person on a substantial daily dose runs 30 to 60 weeks, and many people take a year or more.
Those figures were written for diazepam, and they carry over to chlordiazepoxide because the two drugs are so alike. So, the honest answer is months, often a year, sometimes longer. A promise to get a person who has taken chlordiazepoxide for years off the drug in a few weeks describes a timeline that suits the facility, not the nervous system.
Fortunately, a slow taper is not a slow life. Most people keep working and living while they taper, since each reduction is small. The taper ends when the person reaches zero and stays steady, not when a calendar says so.
The boxed warning on the chlordiazepoxide label, part of the FDA’s 2020 update to every benzodiazepine label, says that abrupt discontinuation or rapid dose reduction after continued use may cause acute withdrawal reactions that can be life-threatening, and it names seizures as the example. The label’s warnings section adds hallucinations to the list of severe reactions. A seizure is a medical emergency, so call emergency services for a seizure or any other medical emergency.
The same label warns that some people develop a protracted withdrawal syndrome, with symptoms lasting from weeks to more than twelve months. In Dr. Leeds’ experience, people who were stopped too fast, by a facility or by themselves, are at higher risk for it. The slow taper exists to prevent both harms.
Many people taking chlordiazepoxide were never told, at the start, that it could cause dependence. Consent at the taper stage begins with the risks of stopping and of continuing, then the alternatives, including staying on the drug, then an exit plan with no fixed end date. The patient may decline any step, pause, or stop the taper entirely, and the care relationship does not change.
At a visit, that right is concrete. The physician proposes the next reduction, the patient says not yet, and the dose holds where it is while the next visit goes ahead as planned. Declining a step is not a failure of the taper; it is the taper working as designed.
Yes. Librium is the original brand name for chlordiazepoxide, and generic chlordiazepoxide capsules contain the same drug in the same 5 mg, 10 mg, and 25 mg strengths. Everything in this article applies to both.
For most people, yes. A gradual taper does not need a facility. It needs a physician who prescribes each reduction, a pharmacy that can compound the small doses, and regular contact to adjust the pace. Dr. Leeds sees his tapering patients by telemedicine throughout Florida.
Dr. Leeds’ practice in Fort Lauderdale, Florida, is a concierge medical practice with one focus: helping patients come off of benzodiazepines and z-drugs slowly, guided by the Ashton Manual and the Maudsley Deprescribing Guidelines and paced to the person taking them. He also helps patients taper other psychiatric medications when those are part of the picture. A person taking chlordiazepoxide who wants to stop it safely can start today. Contact Dr. Leeds.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Mark Leeds, D.O. is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida. He helps patients come off benzodiazepines and sleeping pills with a slow, patient-directed taper guided by the Ashton Manual and the Maudsley Deprescribing Guidelines. Physical dependence is not addiction, and a careful taper is measured in months, not days.
Contact Us for expert guidance on safely tapering off benzodiazepines and reclaiming your life.





